MAIA Biotechnology (MAIA) said Monday its investigational telomere-targeting agent THIO received a rare pediatric disease designation from the Food and Drug Administration to treat pediatric-type diffuse high-grade gliomas.
The company partnered with Only Orphans Cote for THIO's designation request, it added.
MAIA said that THIO is currently in clinical development for evaluating its activity in non-small cell lung cancer.
Shares of the company were up 7% in recent Monday trading.
Price: 2.14, Change: +0.14, Percent Change: +7.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.